Health
ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients – FiercePharma
Bayer and J&J last year showed their legacy blood thinner Xarelto could help post-surgery patients in tough-to-treat artery disease. Now, the partners have data…
With an approval filing already on the FDAs docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients after surgery.
In long-term data from its pivotal trial in peripheral artery disease, Xarelto plus aspirin cut the risk of a variety of clot-related episodesacute clots in the limbs, a major amputation for vascular reasons, heart attack, stroke or cardiovascular deathby 14% compared with aspirin alone in patients who’d had surgery…
-
General18 hours agoIran’s currency at record low as tensions run high
-
Noosa News23 hours agoDisaster relief packages announced for flood-stricken western Queensland
-
Noosa News22 hours agoHundreds pack neighbourhood for no-reserve auction of ready-made charity home
-
General11 hours agoTexas opens probe into Kellogg’s health claims, dyes